Journal
MOLECULAR AND CELLULAR BIOCHEMISTRY
Volume 468, Issue 1-2, Pages 1-11Publisher
SPRINGER
DOI: 10.1007/s11010-020-03698-7
Keywords
Breviscapine; Alzheimer's disease; A beta deposition; p38MAPK; Neurotrophin
Categories
Funding
- Union Foundation of Yunnan Applied Research Project [2017FE468(-183)] Funding Source: Medline
- Yunnan Biopharmaceutical Major Project [2018ZF002] Funding Source: Medline
Ask authors/readers for more resources
Alzheimer's disease (AD) is one of the most serious neurodegenerative diseases and is characterized by progressive cognitive impairment and multiple neurological changes. To date, there are no effective drugs to delay or cure AD. Breviscapine (Bre) is an active ingredient of flavonoids extracted from breviscapus. Previous research suggests that Bre is an effective medicine for the prevention and treatment of AD. In the present study, we sought to explore the molecular mechanisms responsible for short-term beneficial effects of Breviscapine on A beta burden, neuronal and synaptic, cognitive function in APP/PS1 transgenic mice at 6 months age. Our results showed that 3 months of intraperitoneal treatment with Bre rescued learning deficits, relieved memory retention, improved the ability to explore the outside world, markedly decreased A beta burden, attenuated function of neocortical and hippocampal neuron, and increased the synaptic proteins levels in the brain of APP/PS1 mice by decreasing BACE1, promoting A beta-degrading enzyme IDE expression, suppressing RAGE expression, and regulating p38/p53/NT4 pathway. This finding provides more evidence of neuroprotective effects and action mechanisms of Bre antagonist AD, suggesting that Bre may have potential as anti-AD agent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available